Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 91

Similar articles for PubMed (Select 23633451)

1.

Interpreting cancer biology: refining our therapeutic algorithm in breast cancer.

Hortobágyi G, Conte P.

Oncologist. 2013;18(4):e8-10. doi: 10.1634/theoncologist.2013-0117. No abstract available.

2.

[Locally advanced breast cancer (methods of treatment)].

Portnoĭ SM.

Vopr Onkol. 2011;57(5):553-8. Review. Russian. No abstract available.

PMID:
22238923
3.

Refining breast cancer risk assessment with molecular markers: the next step?

Ellis MJ, Hayes DF.

J Natl Cancer Inst. 1999 Dec 15;91(24):2067-8. No abstract available.

4.

Breast cancer biology and the future of tailored therapies. Introduction.

Bergh J, Hall P, Östman A, Toftgård R.

J Intern Med. 2013 Aug;274(2):102-4. doi: 10.1111/joim.12101. No abstract available.

PMID:
23844913
5.

[Breast cancer: the time of genetic testing and targeted treatments].

Nau JY.

Rev Med Suisse. 2014 Feb 19;10(418):460-1. French. No abstract available.

PMID:
24640285
6.

Personalized therapy for breast cancer: a dream or a reality?

Zardavas D, Pugliano L, Piccart M.

Future Oncol. 2013 Aug;9(8):1105-19. doi: 10.2217/fon.13.57.

PMID:
23902243
7.

Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy.

Huber KE, Carey LA, Wazer DE.

Semin Radiat Oncol. 2009 Oct;19(4):204-10. doi: 10.1016/j.semradonc.2009.05.004. Review.

PMID:
19732684
8.

Molecular predictors of local tumor control in early-stage breast cancer.

Miyamoto DT, Harris JR.

Semin Radiat Oncol. 2011 Jan;21(1):35-42. doi: 10.1016/j.semradonc.2010.08.005. Review.

PMID:
21134652
9.

[Endocrinology of breast cancer as a heterogeneous disease: a decade after the millennium].

Bershteĭn LM.

Vopr Onkol. 2013;59(3):292-8. Review. Russian. No abstract available.

PMID:
23909028
10.

Genomic approaches in the management and treatment of breast cancer.

Chang JC, Hilsenbeck SG, Fuqua SA.

Br J Cancer. 2005 Feb 28;92(4):618-24. Review.

11.

[Diagnostic molecular biology in breast cancer].

Andersen TI, Børresen-Dale AL.

Tidsskr Nor Laegeforen. 1998 Jun 10;118(15):2366-9. Review. Norwegian.

PMID:
9691806
12.
14.

ATP synthase ecto-α-subunit: a novel therapeutic target for breast cancer.

Pan J, Sun LC, Tao YF, Zhou Z, Du XL, Peng L, Feng X, Wang J, Li YP, Liu L, Wu SY, Zhang YL, Hu SY, Zhao WL, Zhu XM, Lou GL, Ni J.

J Transl Med. 2011 Dec 8;9:211. doi: 10.1186/1479-5876-9-211.

15.

Clinical evaluation of a panel of mRNA markers in the detection of disseminated tumor cells in patients with operable breast cancer.

Varangot M, Barrios E, Sóñora C, Aizen B, Pressa C, Estrugo R, Lavigna R, Musé I, Osinaga E, Berois N.

Oncol Rep. 2005 Aug;14(2):537-45.

PMID:
16012742
16.

[Strategies of breast cancer treatment based on determination of biological subtype].

Semiglazov VF.

Vopr Onkol. 2011;57(5):542-52. Russian. No abstract available.

PMID:
22238922
17.

[HER2-positive breast cancer: standard and double targeted therapy].

Semiglazov VF, Bozhok AA, Semiglazova TIu, Vasil'ev AG, Manikhas AG, Semiglazov VV, Bessonov AA, Nikolaev KS.

Vopr Onkol. 2013;59(3):341-6. Russian.

PMID:
23909035
18.

Circulating tumor cells in breast cancer: Advanced tools for "tailored" therapy?

Cristofanilli M, Mendelsohn J.

Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17073-4. Epub 2006 Nov 7. No abstract available.

19.

Molecular and clinicopathological markers of prognosis in breast cancer.

Boyle DP, McCourt CM, Matchett KB, Salto-Tellez M.

Expert Rev Mol Diagn. 2013 Jun;13(5):481-98. doi: 10.1586/erm.13.29.

PMID:
23782255
20.

Breast cancer and microRNAs: therapeutic impact.

Iorio MV, Casalini P, Piovan C, Braccioli L, Tagliabue E.

Breast. 2011 Oct;20 Suppl 3:S63-70. doi: 10.1016/S0960-9776(11)70297-1. Review.

PMID:
22015296
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk